

# References

1. Poynard T, Bedossa P, Bioulac-Sage P, et al. Age and platelet count: A simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. *J Viral Hepat* 1997;4(3):199-208.
2. Moser KM, Fedullo PF, Litlejohn JK, et al. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. *JAMA* 1994;271(3):223-5.
3. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. *Arch Intern Med* 2000;160(6):769-74.
4. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. *Arch Intern Med* 2000;160(6):761-8.
5. Mohr DN, Silverstein MD, Heit JA, et al. The venous stasis syndrome after deep venous thrombosis or pulmonary embolism: a population-based study. *Mayo Clin Proc* 2000;75(12):1249-56.
6. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med* 1998;158(6):585-93.
7. Bick RL. Current status of thrombosis: a multidisciplinary medical issue and major American health problem-beyond the year 2000. *Clin Appl Thromb Hemost* 2002;3:1-5.
8. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. *N Engl J Med* 2001;344(16):1222-31.
9. Crowther MA, Roberts J, Roberts R, et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. *Thromb Haemost* 2001;85(3):390-4.
10. Koster T, Rosendaal FR, Briet E, et al. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. *Br J Haematol* 1994;87(2):422-4.
11. Ridker PM, Vaughan DE, Stampfer MJ, et al. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. *Circulation* 1992;85(5):1822-7.
12. Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenemias. *Br J Haematol* 2001;114(2):249-57.
13. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med* 1998;338(15):1042-50.
14. Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. *Blood* 2000;96(3):966-72.
15. Undas A, Williams EB, Butenas S, et al. Homocysteine inhibits inactivation of factor Va by activated protein C. *J Biol Chem* 2001;276(6):4389-97.
16. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. *Blood* 2002;99(1):36-43.
17. Warkentin TE. Heparin-induced thrombocytopenia: a clinicopathologic syndrome. *Thromb Haemost* 1999;82(2):439-47.
18. Kearon C, Julian JA, Newman TE, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. *Ann Intern Med* 1998;128(8):663-77.
19. Baldt MM, Zontsich T, Stumpf A, et al. Deep venous thrombosis of the lower extremity: efficacy of spiral CT venography compared with conventional venography in diagnosis. *Radiology* 1996;200(2):423-8.

20. Fraser DG, Moody AR, Morgan PS, et al. Diagnosis of lower-limb deep venous thrombosis: a prospective blinded study of magnetic resonance direct thrombus imaging. *Ann Intern Med* 2002;136(2):89-98.
21. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. *Chest* 2001;119(1 Suppl):132S-75S.
22. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. *Br J Surg* 2000;87(11):1448-54.
23. Jadad AR, Moher M, Browman GP, et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. *BMJ* 2000;320(7234):537-40.
24. Sutton AJ, Abrams KR, Jones DR, et al. Systematic reviews of trials and other studies. *Health Technol Assess* 1998;2(19):1-276.
25. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. *J Clin Epidemiol* 1995;48(1):167-71.
26. Oxman AD, Guyatt GH. Validation of an index of the quality of review articles. *J Clin Epidemiol* 1991;44(11):1271-8.
27. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. *N Engl J Med* 1987;316(8):450-5.
28. Gebo KA, Jenckes MW, Chander G, Torbenson MS, Ghanem KG, Herlong HF, Sulkowski MS, El-Kamery S, Harris KA, Guedelhoefer OC, and Bass EB. Evidence report on management of chronic hepatitis C. Web Page. Available at: "Health Care: Evidence-based Practice Subdirectory Page", URL: <http://www.ahrq.gov/clinic/epcix.htm>.
29. Schein OD, Friedman DS, Fleisher LA, et al. Anesthesia Management During Cataract Surgery. Evidence Report/Technology Assessment No. 16 (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-097-0006.) AHRQ Publication No. 01-E017. Rockville, MD: Agency for Healthcare Research and Quality; 2001
30. Berlin J. Does blinding of readers affect the results of meta-analyses? *Lancet* 1997;350:185-6.
31. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. *JAMA* 1999;281(14):1318-25.
32. Green D, Hirsh J, Heit J, et al. Low molecular weight heparin: a critical analysis of clinical trials. *Pharmacol Rev* 1994;46(1):89-109.
33. Hirsh J, Siragusa S, Cosmi B, et al. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. *Thromb Haemost* 1995;74(1):360-3.
34. Lensing AW, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. *Arch Intern Med* 1995;155(6):601-7.
35. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. An updated meta-analysis. *Drugs* 1996;52 Suppl 7:30-7.
36. Howard PA. Dalteparin: a low-molecular-weight heparin. *Ann Pharmacother* 1997;31(2):192-203.
37. Brewer D. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis? *J Fam Pract* 1998;47(3):185-92.

38. Hettiarachchi RJ, Prins MH, Lensing AW, et al. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. *Curr Opin Pulm Med* 1998;4(4):220-5.
39. Hunt D. Low-molecular-weight heparins in clinical practice. *South Med J* 1998;91(1):2-10.
40. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. *Ann Pharmacother* 1998;32(5):588-98, 601.
41. Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. *Ann Intern Med* 1999;130(10):789-99.
42. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. *Arch Intern Med* 2000;160(2):181-8.
43. Rocha E, Martinez-Gonzalez MA, Montes R, et al. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. *Haematologica* 2000;85(9):935-42.
44. van den Belt AGM, Prins MH, Lensing AWA, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism (Cochrane Review). *The Cochrane Library*, Issue 4, 2001 2000.
45. van der Heijden JF, Prins MH, Buller HR. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? *Thromb Res* 2000;100(2):V121-30.
46. Thery C, Simonneau G, Meyer G, et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. *Circulation* 1992;85(4):1380-9.
47. Meyer G, Brenot F, Pacouret G, et al. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. *Thromb Haemost* 1995;74(6):1432-5.
48. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. *N Engl J Med* 1997;337(10):663-9.
49. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. *N Engl J Med* 1992;326(15):975-82.
50. Hull RD, Raskob GE, Brant RF, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. *Arch Intern Med* 2000;160(2):229-36.
51. Belcaro G, Nicolaides AN, Cesarone MR, et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. *Angiology* 1999;50(10):781-7.

52. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. *N Engl J Med* 1996;334(11):682-7.
53. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med*. 1996;334(11):677-81.
54. Pearson SD, Blair R, Halpert A, et al. An outpatient program to treat deep venous thrombosis with low-molecular-weight heparin. *Eff Clin Pract* 1999;2(5):210-7.
55. Grau E, Tenias JM, Real E, et al. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. *Am J Hematol* 2001;67(1):10-4.
56. Vinson DR, Berman DA. Outpatient treatment of deep venous thrombosis: a clinical care pathway managed by the emergency department. *Ann Emerg Med* 2001;37(3):251-8.
57. Smith BJ, Weekley JS, Pilotto L, et al. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin. *Intern Med J* 2002;32(1-2):29-34.
58. Huse DM, Cummins G, Taylor DC, et al. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation. *Am J Manag Care* 2002;8(1 Suppl):S10-6.
59. Bocalon H, Elias A, Chale JJ, et al. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. *Arch Intern Med* 2000;160(12):1769-73.
60. Kovacs MJ, Anderson D, Morrow B, et al. Outpatient treatment of pulmonary embolism with dalteparin. *Thromb Haemost* 2000;83(2):209-11.
61. Lloyd AC, Aitken JA, Hoffmeyer UK, et al. Economic evaluation of the use of nadroparin in the treatment of deep-vein thrombosis in Switzerland. *Ann Pharmacother* 1997;31(7-8):842-6.
62. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. *Arch Intern Med* 1997;157(3):289-94.
63. van den Belt AG, Bossuyt PM, Prins MH, et al. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASM AN Study Group. *Thromb Haemost* 1998;79(2):259-63.
64. Rodger M, Bredeson C, Wells PS, et al. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis. *CMAJ* 1998;159(8):931-8.
65. O'Brien B, Levine M, Willan A, et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. *Arch Intern Med* 1999;159(19):2298-304.
66. Estrada CA, Mansfield CJ, Heudebert GR. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis. *J Gen Intern Med* 2000;15(2):108-15.
67. de Lissoyoy G, Yusen RD, Spiro TE, et al. Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin. *Arch Intern Med* 2000;160(20):3160-5.

68. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. *Arch Intern Med* 2000;160(19):2926-32.
69. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. *Chest* 2001;119(1 Suppl):176S-93S.
70. Brandjes DP, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. *N Engl J Med* 1992;327(21):1485-9.
71. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. *N Engl J Med* 2001;345(3):165-9.
72. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. *Lancet* 1992;340(8824):873-6.
73. Fennerty AG, Dolben J, Thomas P, et al. A comparison of 3 and 6 weeks' anticoagulation in the treatment of venous thromboembolism. *Clin Lab Haematol* 1987;9(1):17-21.
74. Holmgren K, Andersson G, Fagrell B, et al. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. *Acta Med Scand* 1985;218:279-84.
75. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *N Engl J Med* 1999;340(12):901-7.
76. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. *Lancet* 1985;2(8454):515-8.
77. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. *Thromb Haemost* 1995;74(2):606-11.
78. O'Sullivan EF. Duration of anticoagulant therapy in venous thrombo--embolism. *Med J Aust* 1972;2(20):1104-7.
79. Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. *Am J Med* 1986;81(2):255-9.
80. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. *Circulation* 2001;103(20):2453-60.
81. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis. A randomized study. *Acta Med Scand* 1985;217(5):547-52.
82. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. *N Engl J Med* 1995;332(25):1661-5.
83. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. *N Engl J Med* 1997;336(6):393-8.

84. Stiell IG, Greenberg GH, McKnight RD, et al. A study to develop clinical decision rules for the use of radiography in acute ankle injuries. *Ann Emerg Med* 1992;21(4):384-90.
85. Clancy CM, Centor RM, Campbell MS, et al. Rational decision making based on history: adult sore throats. *J Gen Intern Med* 1988;3(3):213-7.
86. Dyke PC 2nd, Stevermer JJ. Can a clinical rule accurately predict whether a patient has strep throat? *J Fam Pract* 2001;50(1):69.
87. Nypaver TJ, Shepard AD, Kiell CS, et al. Outpatient duplex scanning for deep vein thrombosis: parameters predictive of a negative study result. *J Vasc Surg* 1993;18(5):821-6.
88. van der Heijden D, Hutten BA, Buller HR, et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Review). *Cochrane Database Syst Rev* 2002;(1):CD002001.
89. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. *Lancet* 1997;350:1795-8.
90. Anderson DR, Wells PS, Stiell I, et al. Thrombosis in the emergency department: use of a clinical diagnosis model to safely avoid the need for urgent radiological investigation. *Arch Intern Med* 1999;159(5):477-82.
91. Aschwanden M, Labs KH, Jeanneret C, et al. The value of rapid D-dimer testing combined with structured clinical evaluation for the diagnosis of deep vein thrombosis. *J Vasc Surg* 1999;30(5):929-35.
92. Lennox AF, Delis KT, Serunkuma S, et al. Combination of a clinical risk assessment score and rapid whole blood D-dimer testing in the diagnosis of deep vein thrombosis in symptomatic patients. *J Vasc Surg* 1999;30(5):794-803.
93. Rathbun SW, Raskob GE, Whitsett TL. Sensitivity and specificity of helical computed tomography in the diagnosis of pulmonary embolism: a systematic review. *Ann Intern Med* 2000;132(3):227-32.
94. Anderson DR, Wells PS, Stiell I, et al. Management of patients with suspected deep vein thrombosis in the emergency department: combining use of a clinical diagnosis model with D-dimer testing. *J Emerg Med* 2000;19(3):225-30.
95. Constans J, Nelzy ML, LR Salmi, et al. Clinical prediction of lower limb deep vein thrombosis in symptomatic hospitalized patients. *Thromb Haemost* 2001;86:985-90.
96. Dryjski M, O'Brien-Irr MS, Harris LM, et al. Evaluation of a screening protocol to exclude the diagnosis of deep venous thrombosis among emergency department patients. *J Vasc Surg* 2001;34(6):1010-5.
97. Funfsinn N, Caliezi C, Biasiutti FD, et al. Rapid D-dimer testing and pre-test clinical probability in the exclusion of deep venous thrombosis in symptomatic outpatients. *Blood Coagul Fibrinolysis* 2001;12(3):165-70.
98. Kearon C, Ginsberg JS, Douketis J, et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and a d-dimer testing. *Ann Intern Med* 2001;135(2):108-11.
99. Cornuz J, Ghali WA, Hayoz D, et al. Clinical prediction of Deep Venous Thrombosis using two risk assessment methods in combination with rapid quantitative d-dimer testing. *Am J Med* 2002;112(3):198-203.
100. Kraaijenhagen RA, Piovella F, Bernardi E, et al. Simplification of the diagnostic management of suspected deep vein thrombosis. *Arch Intern Med* 2002;162(8):907-11.

101. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. *Ann Intern Med* 2001;135(2):98-107.
102. Wells PS, Anderson DR, Bormanis J, et al. Application of a diagnostic clinical model for the management of hospitalized patients with suspected deep-vein thrombosis. *Thromb Haemost* 1999;81(4):493-7.
103. Wells PS, Hirsh J, Anderson DR, et al. Accuracy of clinical assessment of deep-vein thrombosis. *Lancet* 1995;345(8961):1326-30.
104. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. *Ann Intern Med* 1998;129(12):997-1005.
105. Sanson BJ, Lijmer JG, Mac Gillavry MR, et al. Comparison of a clinical probability estimate and two clinical models in patients with suspected pulmonary embolism. ANTELOPE-Study Group. *Thromb Haemost* 2000;83(2):199-203.
106. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. *Thromb Haemost* 2000;83(3):416-20.
107. Stollberger C, Finsterer J, Lutz W, et al. Multivariate analysis-based prediction rule for pulmonary embolism. *Thromb Res* 2000;97(5):267-73.
108. Reprinted with permission from Elsevier Science. (*Lancet* 1995, 345:1328).
109. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 1982;143(1):29-36.
110. White RH, McGahan JP, Daschbach MM, et al. Diagnosis of deep-vein thrombosis using duplex ultrasound. *Ann Intern Med* 1989;111(4):297-304.
111. Cogo A, Lensing AW, Wells P, et al. Noninvasive objective tests for the diagnosis of clinically suspected deep-vein thrombosis. *Haemostasis* 1995;25(1-2):27-39.
112. Wells PS, Lensing AW, Davidson BL, et al. Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis. *Ann Intern Med* 1995;122(1):47-53.
113. Gottlieb RH, Widjaja J, Tian L, et al. Calf sonography for detecting deep venous thrombosis in symptomatic patients: experience and review of the literature. *J Clin Ultrasound* 1999;27(8):415-20.
114. Mustafa B., Rathbun S., Whitsett T., Raskob G. Sensitivity and Specificity of Ultrasonography in the Diagnosis of Upper Extremity Deep Vein Thrombosis. 2002;162:401-404.
115. Becker DM, Philbrick JT, Abbitt PL. Real-time ultrasonography for the diagnosis of lower extremity deep venous thrombosis. The wave of the future? *Arch Intern Med* 1989;149(8):1731-4.
116. Baarslag HJ, van Beek EJ, Koopman MM, et al. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. *Ann Intern Med* 2002;136(12):865-72.
117. Remy-Jardin M, Remy J, Wattrinne L, et al. Central pulmonary thromboembolism: diagnosis with spiral volumetric CT with the single-breath-hold technique—comparison with pulmonary angiography. *Radiology* 1992;185(2):381-7.

118. Kuzo RS, Goodman LR. CT evaluation of pulmonary embolism: technique and interpretation. *AJR Am J Roentgenol* 1997;169(4):959-65.
119. Cueto SM, Cavanaugh SH, Benenson RS, et al. Computed tomography scan versus ventilation-perfusion lung scan in the detection of pulmonary embolism. *J Emerg Med* 2001;21(2):155-64.
120. Harvey RT, Gefter WB, Hsung JM, et al. Accuracy of CT angiography versus pulmonary angiography in the diagnosis of acute pulmonary embolism: evaluation of the literature with summary ROC curve analysis. *Acad Radiol* 2000;7(10):786-97.
121. Mullins MD, Becker DM, Hagspiel KD, et al. The role of spiral volumetric computed tomography in the diagnosis of pulmonary embolism. *Arch Intern Med* 2000;160(3):293-8.
122. van Beek EJ, Brouwers EM, Song B, et al. Lung scintigraphy and helical computed tomography for the diagnosis of pulmonary embolism: a meta-analysis. *Clin Appl Thromb Hemost* 2001;7(2):87-92.
123. Safriel Y, Zinn H. CT pulmonary angiography in the detection of pulmonary emboli: a meta-analysis of sensitivities and specificities. *Clin Imaging* 2002;26(2):101-5.
124. Blum AG, Delfau F, Grignon B, et al. Spiral-computed tomography versus pulmonary angiography in the diagnosis of acute massive pulmonary embolism. *Am J Cardiol* 1994;74(1):96-8.
125. Christiansen F. Diagnostic imaging of acute pulmonary embolism. *Acta Radiol Suppl* 1997;410:1-33.
126. Drucker EA, Rivitz SM, Shepard JA, et al. Acute pulmonary embolism: assessment of helical CT for diagnosis. *Radiology* 1998;209(1):235-41.
127. Goodman LR, Curtin JJ, Mewissen MW, et al. Detection of pulmonary embolism in patients with unresolved clinical and scintigraphic diagnosis: helical CT versus angiography. *AJR Am J Roentgenol* 1995;164(6):1369-74.
128. Qanadli SD, Hajjam ME, Mesurolle B, et al. Pulmonary embolism detection: prospective evaluation of dual-section helical CT versus selective pulmonary arteriography in 157 patients. *Radiology* 2000;217(2):447-55.
129. Remy-Jardin M, Remy J, Deschildre F, et al. Diagnosis of pulmonary embolism with spiral CT: comparison with pulmonary angiography and scintigraphy. *Radiology* 1996;200(3):699-706.
130. Velmahos GC, Vassiliu P, Wilcox A, et al. Spiral computed tomography for the diagnosis of pulmonary embolism in critically ill surgical patients: a comparison with pulmonary angiography. *Arch Surg* 2001;136(5):505-11.
131. Gupta A, Frazer CK, Ferguson JM, et al. Acute pulmonary embolism: diagnosis with MR angiography. *Radiology* 1999;210(2):353-9.
132. Meaney JF, Weg JG, Chenevert TL, et al. Diagnosis of pulmonary embolism with magnetic resonance angiography. *N Engl J Med* 1997;336(20):1422-7.
133. Oudkerk M, van Beek EJR, Wielopolski P, et al. Comparison of contrast-enhanced magnetic resonance angiography and conventional pulmonary angiography for the diagnosis of pulmonary embolism: a prospective study. *Lancet* 2002;359:1643-47.
134. Grist TM, Sostman HD, MacFall JR, et al. Pulmonary angiography with MR imaging: preliminary clinical experience. *Radiology* 1993;189(2):523-30.

135. Loubeyre P, Revel D, Douek P, et al. Dynamic contrast-enhanced MR angiography of pulmonary embolism: comparison with pulmonary angiography. *AJR Am J Roentgenol* 1994;162(5):1035-9.
136. Berthezene Y, Croisille P, Wiart M, et al. Prospective comparison of MR lung perfusion and lung scintigraphy. *J Magn Reson Imaging* 1999;9(1):61-8.
137. Erdman WA, Peshock RM, Redman HC, et al. Pulmonary embolism: comparison of MR images with radionuclide and angiographic studies. *Radiology* 1994;190(2):499-508.
138. Perrier A, Howarth N, Didier D, et al. Performance of helical computed tomography in unselected outpatients with suspected pulmonary embolism. *Ann Intern Med* 2001;135:88-97.
139. Shitrit D, Heyd J, Raveh D, et al. Diagnostic value of the D-dimer test in deep vein thrombosis: improved results by a new assay method and by using discriminate levels. *Thromb Res* 2001;102(2):125-31.
140. Marder VJ, Zareba W, Horan JT, et al. Automated latex agglutination and ELISA testing yield equivalent D-dimer results in patients with recent myocardial infarction. *THROMBO Research Investigators. Thromb Haemost* 1999;82(5):1412-6.
141. Kraaijenhagen RA, Lensing AW, Lijmer JG, et al. Diagnostic strategies for the management of patients with clinically suspected deep-vein thrombosis. *Curr Opin Pulm Med* 1997;3(4):268-74.
142. Becker DM, Philbrick JT, Bachhuber TL, et al. D-dimer testing and acute venous thromboembolism. A shortcut to accurate diagnosis? *Arch Intern Med* 1996;156(9):939-46.
143. Ginsberg JS, Kearon C, Douketis J, et al. The use of D-dimer testing and impedance plethysmographic examination in patients with clinical indications of deep vein thrombosis. *Arch Intern Med* 1997;157(10):1077-81.
144. Gretch DR, dela Rosa C, Carithers RL Jr, et al. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. *Ann Intern Med* 1995;123(5):321-9.
145. Jouet P, Roudot-Thoraval F, Dhumeaux D, et al. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. *Le Groupe Francais pour l'Etude du Traitement des Hepatites Chroniques NANB/C. Gastroenterology* 1994;106(3):686-90.